Kathryn is an executive drug development leader with over 25 years of experience across advanced therapy medicinal products, including gene and cell therapies, biologics, vaccines and GMO-regulated products. Her expertise spans the full development lifecycle, from early research and translational development through global Phase I to Phase IV clinical programmes and commercialisation. She serves as Vice President, Regulatory Affairs and Program Head at Complement Therapeutics, where she drives integrated regulatory and development strategy.

Previously, Kathryn held senior leadership roles at Gyroscope Therapeutics and later Novartis, including Acting Vice President and Head of Regulatory Affairs, supporting multiple ophthalmic gene therapy programmes. She holds an MPhil in Microbiology and a PhD in Molecular Immunology and Gene Therapy, and is an active contributor to ATMP thought leadership, education and fast-to-market regulatory strategy.